Early Menarche May Add to Risk of ER− Breast CA in Black Women

This article originally appeared here.
Share this content:
Early Menarche May Add to Risk of ER− Breast CA in Black Women
Early Menarche May Add to Risk of ER− Breast CA in Black Women

TUESDAY, Aug. 18, 2015 (HealthDay News) -- Age at menarche could play a role in development of estrogen receptor-negative (ER−) breast cancers among African-American women, according to a study published in the September issue of the Journal of the National Cancer Institute.

Christine B. Ambrosone, Ph.D., from the Roswell Park Cancer Institute in Buffalo, N.Y., and colleagues analyzed data gathered from the AMBER Consortium (4,426 African-American women with breast cancer and 17,474 controls). The authors performed polytomous logistic regression to estimate odds ratios (ORs) for ages at menarche and first live birth (FLB), and the interval between, in relation to ER+ and ER− breast cancer.

The researchers found that risk of ER− breast cancer was reduced with later age at menarche among both parous and nulliparous women (≥15 versus <11 years; ORs, 0.62 [95 percent confidence interval, 0.48 to 0.81] and 0.56 [95 percent confidence interval, 0.29 to 1.10], respectively), with no effect of age at FLB. The inverse association was weaker among nulliparous women with ER+ breast cancer. Longer intervals between menarche and FLB were associated with increased risk of ER+ breast cancer in a dose-response manner (OR for 20 year interval, 1.39; Ptrend = 0.003); however, ER− risk was only increased for intervals up to 14 years (Ptrend = 0.33).

"These findings indicate that etiologic pathways involving adolescence and pregnancy may differ for ER− and ER+ breast cancer," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease


More in Home

FDA Approves 'Artificial Pancreas' for Type 1 Diabetes

FDA Approves 'Artificial Pancreas' for Type 1 Diabetes

MiniMed 670G hybrid closed loop system automatically monitors glucose, delivers insulin

More Evidence HPV Vaccine Protects Against Cervical Cancer

More Evidence HPV Vaccine Protects Against Cervical Cancer

Protection appears to occur even when only one or two of the recommended doses are given

Prescribed NSAIDs Tied to Higher Heart Failure Risk

Prescribed NSAIDs Tied to Higher Heart Failure Risk

Study of millions of health records suggests an association

is free, fast, and customized just for you!

Already a member?

Sign In Now »